Osteoblast proliferation

Osteoblast proliferation describes the process by which osteoblasts, the bone-forming cells, increase in number during bone growth, remodeling, and repair. This process is tightly regulated by a host of growth factors (e.g., IGF-1, BMPs), signal transduction pathways (e.g., Wnt/β-catenin, VEGF/ERK, AKT/GSK3), and transcription factors (e.g., RUNX2, Osterix). It is crucial during skeletal development and bone healing and is influenced by both mechanical stress and a variety of hormones. Many agents—including pilose antler peptide, parathyroid hormone, and IGF-1—affect the rate of osteoblast proliferation indirectly by modulating these signaling pathways, but there is no "osteoblast proliferation" molecule or receptor as a direct pharmacological target[6][8][3][7][5][4]. For subsequent data structuring, note that "osteoblast proliferation" is not a canonical molecular target and should be correctly mapped to the relevant molecules (e.g., Wnt signaling components, IGF-1 receptor, parathyroid hormone receptor) depending on the context of drug action or biomarker selection.

Other names

Osteoblast cell proliferationBone-forming cell proliferationOsteogenesis (proliferation phase)

Via upstream signaling pathways, including activation of Wnt/β-catenin, VEGF/ERK, and IGF-1 signaling.